Search the Newsreel

Sana Biotechnology Q2 Results: Adj. EPS beats estimate

Sana Biotechnology reported stronger-than-expected Q2 2026 results, with non-GAAP EPS of $(0.13) surpassing analyst estimates. The company secured $93.3 million in new funding, increasing its cash reserves to $160.5 million and extending its financial runway until mid-2027. This financial stability supports the advancement of …

Sana Biotechnology falls 5% despite beating earnings estimates

Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results

Sana Biotechnology (NASDAQ:SANA) reported a quarterly loss of $0.13 per share, surpassing the consensus estimate of a $0.15 loss. Following the announcement, SANA shares increased by 2.6% to $3.61. The company holds a "Moderate Buy" consensus rating from analysts with an average price target …

Sana Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary

ADPT (ADPT) insider outlines Form 144 sale of 3,000 shares

A holder of Adaptive Biotechnologies Corp (ADPT) common stock has filed a Form 144, indicating an intention to sell 3,000 shares valued at $74,790.00 through Morgan Stanley Smith Barney. These shares are Restricted Stock Units acquired from the issuer on March 4, 2023. The …

Sana Biotechnology (SANA) warns on going concern amid $110.8M loss

Earnings Flash (SANA) Sana Biotechnology, Inc. Posts Q2 Adjusted Loss $0.13 per Share, vs. FactSet Est of $-0.12

Sana Biotechnology, Inc. (SANA) reported a Q2 adjusted loss of $0.0.13 per share, which was narrower than the FactSet estimate of a $0.12 loss per share. The company focuses on developing engineered cells as medicines for therapeutic areas such as type 1 diabetes, oncology, …

Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates

Sana Biotechnology reported its Q2 2026 financial results, highlighting significant progress in its clinical programs for SC451 in type 1 diabetes and SG293 in non-Hodgkin lymphoma, with both expected to start clinical trials this year. The company also announced a follow-on publication in The …

Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

Evotec (NASDAQ:EVO) shares gapped up before the market opened, opening at $2.10 after closing at $2.00, and last traded at $2.0950 on modest volume. Analyst sentiment for the Germany-based biotechnology company is mixed, with a consensus "Hold" rating and a $3.00 average price target, …

Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS

Renaissance Technologies LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 190.9% in the first quarter, now holding 9,600 shares valued at approximately $2.48 million. Other institutional investors have also adjusted their positions, with institutions collectively owning 86.29% of the stock. Analysts …

Evotec and Odyssey Therapeutics team up to accelerate AI-driven drug discovery for autoimmune diseases

Evotec SE and Odyssey Therapeutics have formed a strategic R&D collaboration to accelerate AI-driven drug discovery for autoimmune and inflammatory diseases. The partnership will combine Evotec’s data-driven drug discovery platform, AI-enabled technologies, and screening capabilities with Odyssey’s expertise in disease biology to identify and …

Legend Biotech in spotlight: Earnings test Carvykti momentum

Legend Biotech is set to report its second-quarter earnings, with investors focused on the sustained growth of its CAR-T therapy, Carvykti, amidst increasing competition and a recent CEO departure. Analysts anticipate improved earnings and revenue for the quarter, but concerns linger regarding competitive threats …

Alvotech to Report Financial Results for H1 2026

Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company, announced it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A on Thursday, …

Alvotech Schedules Live Q&A After Its H1 2026 Results Release

Alvotech (NASDAQ: ALVO) will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A session on Thursday, August 20, 2026, at 08:00 ET. …

Fortress Biotech Inc expected to post a loss of 20 cents a share - Earnings Preview

Fortress Biotech Inc (FBIO) is expected to report a loss of 20 cents per share in its upcoming earnings. This article is a preview of the company's financial performance.

Legend Biotech (LEGN) CEO Shift: Will CARVYKTI Leadership Rebalance Risk Between Pipeline and Commercial Focus?

Legend Biotech recently announced a leadership change, with CEO Ying Huang stepping down and Alan Bash, President of the CARVYKTI Business Unit, appointed as Interim CEO. This shift places an executive closely associated with the flagship CARVYKTI franchise at the helm, potentially rebalancing the …

Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026)

Veraxa Biotech Holding AG (NASDAQ: VRXA) announced the effectiveness of its F-1 filing with the SEC, dated August 6, 2026, at 4:00 P.M. The filing indicates a neutral impact and sentiment, as analyzed by StockTitan's AI. This notice of effectiveness relates to the company's …

The Technical Signals Behind (FBIOP) That Institutions Follow

This article analyzes the technical signals for Fortress Biotech Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (NASDAQ: FBIOP), indicating a strong near-term sentiment that could lead to a long-term positive bias. It highlights a significant risk-reward setup targeting a 12.4% gain with …

Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Krystal Biotech stock has delivered a very large 5 year return while recent valuation checks and the latest share price action suggest the current …

Edesa Biotech (EDSA) to Post Earnings on Monday

Edesa Biotech (EDSA) is scheduled to release its quarterly earnings after market close on Monday, August 10th, with analysts anticipating a loss of $0.435 per share. The company previously missed estimates with a loss of $0.49 per share. Despite mixed analyst opinions, MarketBeat reports …

Price to sales forward of Burning Rock Biotech Ltd. Sponsored ADR – FWB:6BU0

This article provides financial information for Burning Rock Biotech Ltd. Sponsored ADR (FWB:6BU0) on TradingView. It specifies the "Price to sales forward" metric for the company, indicating the data was made by humans. The content primarily focuses on navigation and platform features rather than …

XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for XBiotech Inc (XBIT), focusing on future EPS and revenue growth estimates. As of August 9, 2026, the company's stock is trading at 2.275 USD, with a market cap of 69.36M. The forecast section includes details on EPS, …

Adroit Infotech Standalone June 2026 Net Sales at Rs 0.64 crore, down 59.48% Y-o-Y

MBRX Q1 2026 Earnings: Wider-Than-Expected EPS Loss, Yet Shares Climb 10.7% - EPS Guidance Update

Sana Biotechnology (SANA) Advances 2.56% as Shares Approach Key Resistance at $3.79 - Dip Buy Trade

Edesa Biotech (EDSA) Edges Up 2.28% to $5.39 as Clinical-Stage Biotech Draws Interest - IV Contraction

Puma Biotechnology Inc (PBYI) Earnings Forecast: Future EPS & Revenue Growth Estimates

Puma Biotechnology Inc (PBYI) currently holds an earnings forecast score of 6.00, placing it 130th out of 156 companies in the Pharmaceuticals industry. Analysts have set an average price target of $5.00 for PBYI, with a range from $2.00 to $7.00. The company's next …

Half Yearly Results, Half yearly Earnings for 3i Infotech

Moleculin Biotech Inc (MBRX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Adaptive Biotechnologies (ADPT) Is Up 10.5% After Raising 2026 MRD Revenue Guidance Has The Bull Case Changed?

Hong Kong Stock Market Movement | GenScript Biotech Corporation (01548.HK) Rises Over 8% as AIDD Boosts Demand for Experimental Validation; Institutions Bullish on Strengthened 'Shovel Seller' Thesis

Shanghai Henlius Biotech (SEHK:2696) Advances Oncology Pipeline, Is It Still 64% Below Fair Value?

Moleculin Biotech, Inc. Actuals & Estimates (NASDAQ:MBRX)

Enterprise value to revenue forward of MicroTech Medical (Hangzhou) Co., Ltd. Class H – HKEX:2235

Sana Biotechnology faces earnings test as CAR-T program advances

Sana Biotechnology Inc. is set to report its second-quarter results on Monday, with analysts expecting a narrower loss of 15 cents per share and no revenue. Investors will be closely watching for updates on its in vivo CAR-T platform, specifically SG293, and its stem …

Renaissance Technologies LLC Acquires Shares of 239,800 Adaptive Biotechnologies Corporation $ADPT

Renaissance Technologies LLC has acquired 239,800 shares of Adaptive Biotechnologies Corporation, valued at approximately $3.33 million, marking a new stake in the company. Institutional investors collectively hold 99.17% of Adaptive Biotechnologies. The company reported better-than-expected quarterly revenue but missed earnings estimates, while analysts maintain …